18 June, 2004. Biotecnol announced the successful completion and implementation of their novel Trisoma™ platform for faster, reliable and consistent generation and production of highly stable and bioactive Tribody™ products.
Trisoma™ is a very valuable platform for Biotecnol, since so far the production of the new generations of multispecific products, based on various types of formats, has proven to be a challenge for most companies. Biotecnol can now develop its Tribody™ products internally to take them to the clinic as well as comparing them to other competitor formats such bi-specific single chain fragments and IgG based scaffolds in terms of efficacy.
Trisoma™ is a powerful high-throughput, and well-controlled platform for generating and characterizing a Tribody™ candidate drug substance. The Trisoma™ platform is used for the assembly, engineering and testing of each Tribody™ molecule. Mastering the operation of the Trisoma™ platform, is central for the generation of the pipeline of products for Biotecnol. Also, it allows the Company to enter into R&D collaborations with third-parties, under the aegis of collaborative deals.
The new technology has the potential to further improve Biotecnol’s antibody business as it allows the Company to standardize its Tribody™ manufacturability operations and consistently obtain product candidates in 12-16 weeks time. The technology will be presented at the Business Forum during the BIO International Convention in San Diego, California 22-25 June.
Through the implementation of Trisoma™ Biotecnol has now a tight control and a sound and growing understanding of its own Tribody™ format, which is key for the continuous development of an efficient and consistent development path, right from Lead Tribody™ Identification to Investigational New Drug (IND) filing. The successful implementation of Trisoma™ is therefore the first enabling step, for the production of Tribody™ Drug Substance for clinical research, in a robust, scalable and reproducible manner.
About the Tribody™ format
Tribody™ molecules are multi-specific antibodies, produced by established recombinant DNA technology methods, which utilize the natural in vivo heterodimerization of Fab fragments to form a scaffold, upon which additional functionality can be incorporated. As a result Tribodies are characterized by an unsurpassed versatility; they can incorporate up to three different binding sites and can combine different functions, such as the ability to engage and redirect potent immune-effector cells like T-cells or NK-cells whilst retaining the ability to target more than one epitope in a tumor target, or more than one target in the same tumor, all in one single molecule.
About Trisoma™
Trisoma™ is a powerful high-throughput, and well-controlled platform for generating and characterizing a Tribody™ candidate drug substance. The Trisoma™ platform is used for the assembly, engineering and testing of each Tribody™ molecule. Mastering the operation of the Trisoma™ platform, is central for the generation of the pipeline of products for Biotecnol. Also, it allows the Company to enter into R&D collaborations with third-parties, under the aegis of collaborative deals.
About Biotecnol
Biotecnol is an immune-oncology company with a strong track-record in antibody drug development. The company has a proprietary antibody format -Tribody™- for engaging various immunological effector functions including T-cells, to destroy cancer cells. The Company is looking to strengthen this solid asset base of new agents in the immune-oncology field, by developing candidates with a dual approach involving novel targets. Biotecnol has fully integrated capabilities that allow the company to run and effectively manage its own drug development programmes, right from the antibody selection process to clinic proof of concept.
Back to news